Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrr...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo-Stella
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2023-08-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/11243
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!